Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3357-3365

  Goldhirsch, Aron ^a   Wood, William C ^a   Gelber, Richard D ^a   Coates, Alan S ^a   Thürlimann, Beat ^a   Senn, Hans Jörg ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER THERAPY; CARCINOMA IN SITU; CONSENSUS; HUMAN; MEDICAL EXPERT; PATIENT CARE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; BREAST TUMOR; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; INTERNATIONAL COOPERATION; LYMPH NODE METASTASIS; PATHOLOGY; PROGNOSIS; SWITZERLAND;

BREAST NEOPLASMS; FEMALE; GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; LYMPHATIC METASTASIS; PROGNOSIS; SWITZERLAND;

EID: 0141576783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.576     Document Type: Article

References (105)

1. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
2. Harbeck N, Kates RE, Look MP, et al: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62:4617-4622, 2002
3. Look MP, van Putten WL, Duffy MJ, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94:116-128, 2002
4. Perou CM, Sortie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
5. van't Veer LJ, De Jong D: The microarray way to tailored cancer treatment. Nat Med 8:13-14, 2002
6. Bartelink H, Begg AC, Martin JC, et al: Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 6:2-10, 2000
7. van De Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
8. Keyomarsi K, Tucker SL, Buchholz TA, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566-1575, 2002
9. Keyomarsi K, Tucker SL, Bedrosian I: Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 9:152, 2003
10. Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100 (SWOG-S814). Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)
11. Albain KS: Adjuvant chemo-endocrine therapy for breast cancer: Combined or sequential? Breast 12:S13, 2003 (suppl 1, abstr S36)
12. Fisher B, Jeong J-H, Bryant J, et al: Findings from two decades of National Surgical Adjuvant Breast and Bowel Project clinical trials involving breast cancer patients with negative axillary nodes. Proceedings of the San Antonio Breast Cancer Symposium, December 11-14, 2002, San Antonio, TX (abstr 16)
13. International Breast Cancer Study Group: Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 94:1054-1065, 2002
14. Coates AS, Gelber RD, Goldhirsch A: Subsets within the chemotherapy overview: International Breast Cancer Study Group. Lancet 352:1783-1784, 1998
15. Coates AS, Goldhirsch A, Gelber RD: Overhauling the breast cancer overview: Are subsets subversive? Lancet Oncol 3:525-526, 2002
16. Aebi S, Gelber S, Castiglione-Gertsch M, et al: Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869-1874, 2000
17. Goldhirsch A, Gelber RD, Yothers G, et al: Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr 30:44-51, 2001
18. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
19. Cole BF, Gelber RD, Gelber S, et al: Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358:277-286, 2001
20. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003
21. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000
22. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300, 2003
23. Veronesi U, Maisonneuve P, Rotmensz N, et al: Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160-165, 2003
24. Zheng L, Li S, Boyer TG, et al: Lessons learned from BRCA1 and BRCA2. Oncogene 19:6159-6175, 2000
25. Contant CM, Menke-Pluijmers MB, Seynaeve C, et al: Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol 28:627-632, 2002
26. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
27. Cuzick J, Forbes J, Howell A: Tamoxifen for breast-cancer prevention. Lancet 361:178, 2003
28. National Comprehensive Cancer Network. http://www.nccn.org
29. Jordan VC: Is tamoxifen the rosetta stone for breast cancer? J Natl Cancer Inst 95:338-340, 2003
30. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
31. Dixon JM, Jackson J, Hills M, et al: Anastrozole demonstrates clinical and biological effectiveness in erbB2 ER positive breast cancers. Proceedings of the San Antonio Breast Cancer Symposium, December 11-14, 2002, San Antonio, TX (abstr 263)
32. Love RR, Duc NB, Havighurst TC, et al: HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453-457, 2003
33. Bryant J, Land S, Allred C, et al: DCIS: NSABP evidence from randomized trials. Breast 12:S9, 2003 (suppl 1, abstr S24)
34. Veronesi U, Cascinelli N, Mariani L, et al: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232, 2002
35. Fisher B, Jeong JH, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002
36. Galimberti V: Evaluation of regional lymphnodes: New standards? Breast 12:S5, 2003 (suppl 1, abstr S9)
37. van der Ent FW, Kengen RA, van der Pol HA, et al: Halsted revisited: Internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 234:79-84, 2001
38. Bartelink H, Horiot JC, Poortmans P, et al: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378-1387, 2001
39. Koc M, Polat P, Suma S: Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol 64:171-175, 2002
40. Bentzen SM, Skoczylas JZ, Overgaard M, et al: Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 88:918-922, 1996
41. Pierce LJ: Treatment guidelines and techniques in delivery of post-mastectomy radiotherapy in management of operable breast cancer. J Natl Cancer Inst Monogr 30:117-124, 2001
42. Intra M, Gatti G, Luini A, et al: Surgical technique of intraoperative radiotherapy in conservative treatment of limited-stage breast cancer. Arch Surg 137:737-740, 2002
43. Keisch M, Vicini F, Kuske RR, et al: Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 55:289-293, 2003
44. Vicini F, Baglan K, Kestin L, et al: The emerging role of brachytherapy in the management of patients with breast cancer. Semin Radiat Oncol 12:31-39, 2002
45. Bankhead C: Accelerated partial breast irradiation More data needed, researchers say. J Natl Cancer Inst 95:259-261, 2003
46. Hayes DF: Markers of increased risk for failure of adjuvant therapies. Breast 12:514, 2003 (suppl 1, abstr S37)
47. Viale G: Histopathology of primary breast cancer 2003. Breast 12:S4, 2003 (suppl 1, abstr S8)
48. Braun S, Pantel K, Muller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533, 2000
49. Piccart MJ: New data on chemotherapy in the adjuvant setting. Breast 12:S4, 2003 (suppl 1, abstr S5)
50. Colleoni M: Preoperative systemic treatment: Prediction of responsiveness. Breast 12:S13, 2003 (suppl 1, abstr S35)
51. Colleoni M, Gelber S, Coates AS, et al: Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 19:4141-4149, 2001
52. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
53. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. J Clin Oncol 20:3317-3327, 2002
54. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002
55. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002
56. Davidson NE: Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 30:67-71, 2001
57. Castiglione-Gertsch M, O'Neill A, Gelber RD, et al: Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin? First results of IBCSG trial VIII. Proc Am Soc Clin Oncol 21:38a, 2002 (abstr 149)
58. Castiglione-Gertsch M: Chemo-endocrine therapy: Any need to combine? Breast 12:511, 2003 (suppl 1, abstr S30)
59. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
60. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
61. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup trial INT 0102. Proc Am Soc Clin Oncol 17:1a, 1998 (abstr 2)
62. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial-Scandinavian Breast Group 9401 study. Lancet 356:1384-1391, 2000
63. Goldhirsch A, Colleoni M, Coates AS, et al: Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike? Ann Oncol 9:489-493, 1998
64. Adlard JW, Dodwell DJ: Optimum anthracycline-based chemotherapy for early breast cancer. Lancet Oncol 2:469-474, 2001
65. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
66. Mamounas EP: Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes. NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer, November 1-3, 2000, Bethesda, MD
67. Nabholtz J-M, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a, 2002 (abstr 141)
68. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
69. Fumoleau P, Kerbrat P, Romestaing P, et al: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21:298-305, 2003
70. Colleoni M, Litman HJ, Castiglione-Gertsch M, et al: Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86:1705-1714, 2002
71. Pico C, Martin M, Jara C, et al: Epirubicin-cyclophosphamide (EC) chemotherapy plus tamoxifen (T) administered concurrent (Con) versus sequential (Sec): Randomized phase III trial in postmenopausal node-positive breast cancer (BC) patients-GEICAM 9401 study. Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 144)
72. Sertoli MR, Pronzato P, Venturini M, et al: A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer. Proc Am Soc Clin Oncol 21:46a, 2002 (abstr 182)
73. Simes RJ, Coates AS: Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed? J Natl Cancer Inst Monogr 30:146-152, 2001
74. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
75. Colleoni M, Bonetti M, Coates AS, et al: Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol 18:584-590, 2000
76. Colleoni M, Minchella I, Mazzarol G, et al: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11:1057-1059, 2000
77. Lippman ME, Allegra JC: Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46:2859-2868, 1980 (12 suppl)
78. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
79. IBIS Investigators: First results of the International Breast Cancer Intervention Study (IBIS-1). Lancet 360:817-824, 2002
80. Fisher B: Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: An interim report. Breast Cancer Res Treat 3:S7-S17, 1983 (suppl)
81. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7:710-717, 1989
82. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385-1394, 1997
83. Wolff AC, Abeloff MD: Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: It ain't necessarily so. J Natl Cancer Inst 94:1041-1043, 2002
84. International Breast Cancer Study Group: Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 10:130-138, 2001 (suppl 3)
85. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 20:3628-3636, 2002
86. Ravdin PM, Siminoff IA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998
87. Lindley C, Vasa S, Sawyer WT, et al: Quality of life and preferences for treatment following systemic adjuvant therapy for early breast cancer. J Clin Oncol 16:1380-1387, 1998
88. Langer AS: Side effects, quality-of-life issues, and trade-offs: The patient perspective. J Natl Cancer Inst Monogr 30:125-129, 2001
89. Brussels Statement. http://www.mindfully.org/Health/Brussels-Statement- Oct2000.htm
90. National Breast Cancer Coalition, http://www.natlbcc.org/
91. Jefford M, Tattersall MHN: Informing and involving cancer patients in their own care. Lancet Oncol 3:629-637, 2002
92. Molenaar S, Sprangers MA, Rutgers EJT, et al: Decision support for patients with early-stage breast cancer: Effects of an interactive breast cancer CDROM on treatment decision, satisfaction, and quality of life. J Clin Oncol 19:1676-1687, 2001
93. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
94. Levine M, Whelan T: Decision-making process: Communicating risk/benefits-Is there an ideal technique? J Natl Cancer Inst Monogr 30:143-145, 2001
95. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
96. Adami HO, Malker B, Holmberg L, et al: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559-563, 1986
97. Chung M, Chang HR, Bland KI, et al: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77:97-103, 1996
98. Kroman N, Jensen MB, Wohlfahrt J, et al: Factors influencing the effect of age on prognosis in breast cancer: Population based study. BMJ 320:474-478, 2000
99. Colleoni M, Rotmensz N, Robertson C, et al: Very young women (<35 years) with operable breast cancer: Features of disease at presentation. Ann Oncol 13:273-279, 2002
100. Mintzer D, Glassbum J, Mason BA, et al: Breast cancer in the very young patient: A multidisciplinary case presentation. Oncologist 7:547-554, 2002
101. Love RR, Due NB, Allred DC, et al: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002
102. Morrow M, Krontiras H: Who should not receive chemotherapy? Data from American databases and trials. J Natl Cancer Inst Monogr 30:109-113, 2001
103. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer. Overview of the randomised trials. Lancet 348:1189-1196, 1996
104. Bartelink H: Radiotherapy to the conserved breast, chest wall, and regional nodes: Is there a standard? Breast 12:S9, 2003 (suppl 1, abstr S24)
105. Ellis PM, Butow PN, Tattersall MHN, et al: Randomized clinical trials in oncology: Understanding and attitudes predict willingness to participate. J Clin Oncol 19:3554-3561, 2001